Antiviral, Immunomodulatory and Antiproliferative Activities of Recombinant Soluble IFNAR2 without IFN-beta Mediation

dc.contributor.authorHurtado Guerrero, Isaac
dc.contributor.authorHernáez, Bruno
dc.contributor.authorPinto Medel, María J.
dc.contributor.authorCalonge, Esther
dc.contributor.authorRodríguez Bada, José L.
dc.contributor.authorUrbaneja, Patricia
dc.contributor.authorAlonso, Ana
dc.contributor.authorMena Vázquez, Natalia
dc.contributor.authorAliaga, Pablo
dc.contributor.authorIssazadeh Navikas, Shohreh
dc.contributor.authorPavia, José
dc.contributor.authorLeyva, Laura
dc.contributor.authorAlcamí, Antonio
dc.contributor.authorAlcamí, José
dc.contributor.authorFernández, Óscar
dc.contributor.authorOliver Martos, Begoña
dc.date.accessioned2021-01-19T18:15:34Z
dc.date.available2021-01-19T18:15:34Z
dc.date.issued2020-04-01
dc.date.updated2020-12-21T13:11:24Z
dc.description.abstractSoluble receptors of cytokines are able to modify cytokine activities and therefore the immune system, and some have intrinsic biological activities without mediation from their cytokines. The soluble interferon beta (IFN-ss) receptor is generated through alternative splicing of IFNAR2 and has both agonist and antagonist properties for IFN-ss, but its role is unknown. We previously demonstrated that a recombinant human soluble IFN-ss receptor showed intrinsic therapeutic efficacy in a mouse model of multiple sclerosis. Here we evaluate the potential biological activities of recombinant sIFNAR2 without the mediation of IFN-ss in human cells. Recombinant sIFNAR2 down-regulated the production of IL-17 and IFN-? and reduced the cell proliferation rate. Moreover, it showed a strong antiviral activity, fully protecting the cell monolayer after being infected by the virus. Specific inhibitors completely abrogated the antiviral activity of IFN-ss, but not that of the recombinant sIFNAR2, and there was no activation of the JAK-STAT signaling pathway. Consequently, r-sIFNAR2 exerts immunomodulatory, antiproliferative and antiviral activities without IFN-ss mediation, and could be a promising treatment against viral infections and immune-mediated diseases.
dc.format.extent20 p.
dc.format.mimetypeapplication/pdf
dc.identifier.pmid32244308
dc.identifier.urihttps://hdl.handle.net/2445/173228
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/jcm9040959
dc.relation.ispartofJournal of Clinical Medicine, 2020, vol. 9, num. 4
dc.relation.urihttps://doi.org/10.3390/jcm9040959
dc.rightscc by (c) Hurtado Guerrero et al., 2020
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationImmunologia
dc.subject.classificationInterferó
dc.subject.otherImmunology
dc.subject.otherInterferon
dc.titleAntiviral, Immunomodulatory and Antiproliferative Activities of Recombinant Soluble IFNAR2 without IFN-beta Mediation
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
Hurtado-GuerreroI.pdf
Mida:
3.99 MB
Format:
Adobe Portable Document Format